Melanotan II is only defensible for users who specifically want the tanning effect, fully understand that they are operating without a safety net of clinical trial data, and are not in a high-risk category for dermatological adverse events
Patients with Hepatic Impairment In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), mean AUC and Cmax of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sitagliptin
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group
Licensed in 50 states
Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilberts syndrome
This is why research groups around the world are trying to engineer microbes to act as edible drug factories
